Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GBI268
- Development stage
- Phase 3
- Lead developer
- Guangzhou Zhiyao Biotechnology
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Local Infiltration
01
Overview
GBI268 is a long-acting, multivesicular liposome formulation of the local anesthetic bupivacaine, developed by Guangzhou Zhiyao Biotechnology. It is designed for the management of postoperative pain through local infiltration at the surgical site. The multivesicular liposome (MVL) technology enables the sustained release of bupivacaine over an extended period (typically up to 72 hours), providing prolonged analgesia and potentially reducing the requirement for postoperative opioids. Bupivacaine exerts its effect by blocking voltage-gated sodium channels in nerve fibers, thereby inhibiting the initiation and conduction of sensory nerve impulses. GBI268 is currently in Phase III clinical development in China for indications such as postoperative pain following hemorrhoidectomy and bunionectomy.
- Other names
- bupivacaine multivesicular liposome injection
02
Targets
SCN1A (Voltage-gated sodium channel protein type 1 subunit alpha)SCN2A (Voltage-gated sodium channel protein type 2 subunit alpha)SCN3A (Sodium channel protein type 3 subunit alpha)SCN4A (Voltage-gated sodium channel protein type 4 subunit alpha)SCN5A (Sodium channel protein type 5 subunit alpha)SCN8A (NaV1.6)SCN9A (Sodium channel protein type 9 subunit alpha)
Beyond the preview
Go deeper on GBI268.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GBI268.